Cytek Biosciences vs Mesa Laboratories
Mesa Laboratories is the larger business, with $249m of revenue in fiscal 2026 against $201m for Cytek Biosciences (1.2 times as much). Mesa Laboratories grew faster (3.4% against 0.5%). Mesa Laboratories kept more of each dollar of sales as profit: a net margin of 2.7% against -33.0%. Cytek Biosciences carries less debt relative to equity (0.2% against 36.2%).
| Latest fiscal year | Cytek BiosciencesCTKB, 2025 | Mesa LaboratoriesMLAB, 2026 |
|---|---|---|
| Revenue | $201m | $249m |
| Revenue growth | 0.5% | 3.4% |
| Net income | −$66.5m | $6.7m |
| Operating margin | -20.0% | 7.4% |
| Net margin | -33.0% | 2.7% |
| Return on equity | -18.0% | 3.9% |
| Free cash flow | −$8.8m | $39.6m |
| Cash | $90.9m | $26.9m |
| Total debt | $525,000 | $67.5m |
| Debt to equity | 0.2% | 36.2% |
| Dividend per share | — | $0.64 |
| Dividend yield | — | 0.5% |
| Share buybacks | $15.1m | — |
| Employees | 702 | 717 |
| Market value | $774m | $705m |
| Price vs our value range | — | Within our value range |
| Moat score | 36 (Weak) | 44 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 5 buys, 7 sales |